Kornimate/medical-research-clean huggingface dataset:
cross-sectional survey on palliative therapy for pancreatic cancer patient

Conditions: Pancreatic Cancer

Summary: it is a real-world observational cross-sectional follow-up study on clinical palliative care for pancreatic cancer patients in china. it is evaluated by an online questionnaire sent to the doctors from the general surgery department in more than 100 public tertiary teaching hospitals and about 350 public primary care units in the chinese mainland.

pancreatic cancer is a highly malignant gastrointestinal tumor with only a 10% overall 5-year survival rate. more than 80% of patients are already in the advanced stage when diagnosed, losing the chance of surgery. advanced pancreatic cancer progresses rapidly and chemoradiotherapy has limited efficacy, so palliative care is thought to play an important role in the treatment process. however, due to the late development of palliative care, there is a lack of data on real-world clinical palliative care for pancreatic cancer patients in china. this study investigates the real-world current status of palliative care for pancreatic cancer patients by sending a web questionnaire to the doctors from the department of general surgery in more than 100 public tertiary teaching hospitals and about 350 public primary care units in the chinese mainland. the survey aims to obtain the real status of palliative care and achieve a comprehensive understanding of how to develop palliative care in hospitals. the questionnaire includes both subjective standards like the surgeons' opinion on the development of palliative therapy and objective standards such as dedicated beds and teams for palliative care.

Eligibility criteria:
inclusion criteria: * doctors from the general surgery department in chinese public tertiary teaching hospitals and public primary care units * approval to participate * participants with a valid and complete questionnaire evaluated by 2 experienced surgeons exclusion criteria: * refusal to participate * participants with an invalid or incomplete questionnaire

Keywords: follow up palliative care pancreatic cancer
a phase i study of bms-275183 given on a daily schedule in patients with advanced malignancies

Conditions: Tumors

Summary: the purpose of this clinical research study is to learn about the safety and tolerability of daily bms-275183 in patients with advanced cancer.


Eligibility criteria:
inclusion criteria: * non-hematologic malignancy that has progressed or no standard therapy is known * four weeks from last chemotherapy or two weeks from last non-cytotoxic therapy * eastern cooperative oncology group (ecog) performance status 0-1 * no more than 3 prior chemotherapy regimens in advanced/metastatic setting * absolute neutrophil count \>=1,500/mm3 and platelets \>=100,000/mm3 * bilirubin \<=1.5 x upper limit of normal (uln), aspartate aminotransferase \<=2.5 x uln * serum creatinine \<=1.5 x uln * men and women \>=18 years * women of child bearing potential (wocbp) must use adequate method of contraception throughout and up to 4 weeks after the study exclusion criteria: * wocbp and men not using adequate method of birth control * wocbp who are pregnant or breastfeeding * prior radiation \>=25% of bone marrow containing skeleton * uncontrolled, significant, or active cardiovascular or pulmonary disease or infection or psychiatric disorder * neuropathy * active brain metastases * inability to swallow capsules * history of gastrointestinal disease, surgery or malabsorption, or requiring use of a feeding tube * concurrent chemotherapy, hormonal therapy, immunotherapy, or radiotherapy

Keywords: patients with advanced solid tumors
aspiration of limited number of follicles to prevent severe ovarian hyperstimulation syndrome

Conditions: Infertility

Summary: the purpose of this study is to evaluate the effect of single ovarian puncture to retrieve 7eggs only in prevention of severe ovarian hyperstimulation syndrome.

thirty patients will be selected for this study grouped into two groups, each group contains fifteen patients. group 1 :study group ( retrieval of 7 eggs only). group 2 :control group ( retrieval of all eggs). study is held to compare between the two arms, the proportion of patients who will be prevented from the progression to severe ohss after this interventional method.

Eligibility criteria:
inclusion criteria: 1. more than 9 days of induction of ovulation. 2. each ovary contains more than 20 follicles. 3. the majority of follicles are \>14mm in diameter. 4. mild fluid in douglas pouch. 5. the patient started to complain of considerable lower abdominal pains before the egg collection. exclusion criteria: 1. recurrent icsi failure or bad obstetric history. 2. any medical disorder affecting the fluid shift as: diabetes mellitus, autoimmune diseases, hepatic, renal or cardiac conditions.
quantitative analysis of precise brain volume in amyotrophic lateral sclerosis

Conditions: Amyotrophic Lateral Sclerosis

Summary: using the original mri images of 16 als patients and 16 normal controls matched by gender, age and education level in the previous study, the differences of brain volume in different parts of als patients and normal controls, and the correlation between brain structure and clinical characteristics were compared by precise brain volume quantitative analysis technology.

this study was a retrospective study. the subjects were 16 als patients and 16 normal controls. previous studies have collected patients' age, gender and education level; the onset site, onset time, bulbar involvement, diagnostic grade, alsfrs-r score, application of ventilator, application of lirutai, gastrostomy; age, gender and education level were collected in the control group. accurate quantitative analysis of brain volume was performed on the original brain mri images of the two groups.

Eligibility criteria:
inclusion criteria: * diagnosed als patients * healthy volunteers exclusion criteria: * none
vilma: therapeutic results in acute mieloblastic leukemia in patients older than 60 years

Conditions: AML

Summary: this is a retrospective study to analyze the therapeutic results and clinical evolution all patients diagnosed with aml and aged ≥ 60años or not candidates for chemotherapy intensive, treated according to the different schemes available, including supportive care or palliative.

approximately in 6 months, collect and review the retrospective data. during this period, and in order to ensure an excellent quality of the collected data, perform constant monitoring and real-time data received in 2 phases: 1. monitoring "in situ" in the focal point: once the information is received before shall enter in the database, will be reviewed each case report data (crd) for screening for inconsistencies and issue unresolved issues (queries) to sender data center. after entering the information in the database is carry out and resolve those queries that have arisen after consultation data tables in order to locate inconsistencies or unavailable fields. 2. telephone monitoring: data shall be verified through telephone consultations all centers to verify and update recruitment and monitoring patients . to ensure the completion, accuracy and data quality is monitored by telephone at least 30% of registered patients. * final statistical analysis (approximately 8 months from baseline). * publication of results.

Eligibility criteria:
inclusion criteria: * patients aged ≥60 years, diagnosed of aml or not candidates to intensive chemotherapy exclusion criteria: * no exclusion criteria
towards neurobiology-based diagnosis and treatment of affective disorders

Conditions: Affective Disorder

Summary: the project is a multi-center, prospective cohort study. the study's total targeted enrollment is 400 first-episode patients with major depressive disorder (mdd) and 400 healthy controls.

four hundred patients with a primary diagnosis of depression and hamd-17 scores ≥14 at baseline visit are to be assigned to one of the second-generation antidepressant drugs, including escitalopram, duloxetine, mirtazapine, paroxetine, sertraline, etc based on investigators' clinical practice. initial treatment consists of a 8-week course with one of these monotherapies. patients who meet criteria for full remission are followed for a 22-month follow-up phase to monitor for depression recurrence. patients who do not remit are offered another 8 weeks of acute treatment, including combination therapy or switching to other antidepressant based on investigators' clinical practice. the clinical assessment (hamilton depression rating scale(hamd)/ clinical general impression (cgi) /the positive and negative affect schedule (panas) /subtypes of depression, dimensional anhedonia rating scale (dars) , etc), early life stress, neuropsychological test, and biological examination (mri, genetics, neurochemistry, and immunology) were conducted to identify the biomarkers associated with diagnosis, treatment efficacy prediction of depression. among the 400 patients, about 100 patients receive mri scans at baseline and after treatment.

Eligibility criteria:
inclusion criteria: 1. patients with depression * the inclusion criteria for depressed patients were: male or female outpatients aged between 18 and 55 years old * currently in acute depressive episode * total hamd-17 score≥14 at baseline visit. * the diagnosis of depression was confirmed by a trained psychiatrists using the mini-international neuropsychiatric interview (mini). * the patients participating in imaging scans should additionally satisfy: not taking psychiatric drugs within last two weeks (except for benzodiazepine) or fluoxetine last one month * not receiving ect within last 6 months. exclusion criteria: * unable to complete the questionnaire and psychological assessment independently * significant cognitive impairments determined by system mental examination and inability to sign an informed consent form * past or presently suffering from other psychiatric disorders, alcohol and drug dependence * suffering from major physical diseases, such as cardiovascular and cerebrovascular diseases, respiratory diseases, kidney disease, cancer and so on; personality disorder * intellectual disabilities * suicidal behavior * being participating in other studies.
effect of maxomat ® on the growth of small children to noonan's syndrome

Conditions: Noonan Syndrome

Summary: 1. clinical objective : to improve the growth of these children 2. genetic objective : a study of the genetics of the syndrome


Eligibility criteria:
inclusion criteria: * children and adolescents with noonan's syndrome with a height \< -2 sd and no progressive cardiopathy exclusion criteria: * age \< 3 years * height ≥ -2 sd the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
moms hubs- ct dept of social services block grant

Conditions: Depression

Summary: the moms partnership aims to create "moms zones" in new haven neighborhoods where the hardest to reach families live. these "moms zones" will have two unique features: (1) a moms "hub" to deliver centralized mental health and family economic success services to the hardest to reach families living in new haven's most impoverished neighborhoods, as measured by actual socio-economic status as well as by access to resources; (2) a neighborhood workforce of community mental health ambassadors (cmhas--mothers who themselves live in new haven). the moms workforce program and moms mental health program will be offered at all three hubs.

the moms workforce program will involve teaching, coaching, and supportive services for participants as they navigate their journeys to sustainable employment that pays a family-supporting wage. participants will be guided through an individualized progression of services designed to increase their employability, to increase their ability to earn higher incomes in career-track employment, and to improve their chances of retaining jobs and advancing in them. the moms mental health program centers around a manualized stress management course 8-class group treatment, delivered once per week. the course was adapted from "the mother and child course" by munoz and le (2011) for the population of new haven mothers who are served by the moms partnership.

Eligibility criteria:
inclusion criteria are as follows: * participant is a woman raising a child or adolescent under 18 years of age. the child/adolescent may be her biological offspring or in her custody due to adoption or foster care. care arrangements may be legally sanctioned or informal, as is common in new haven families. thus, the eligible participant may be a sister, aunt, grandmother, or other female responsible for the daily care of children. * participant currently resides within the city limits of new haven, ct. * participant resided within county of new haven, ct on october 29, 2012. * participant's income is at or below 325% of the federal poverty income. * participant is a u.s. citizen. * participant's score on ces-d \> 16. exclusion criteria are as follows: * signs or symptoms of active psychosis or active suicidality will be a basis for exclusion in the study. * lack of proficiency in english.
evaluation of blood loss and pain in tka with and without pneumatic tourniquet, a randomized controlled trial

Conditions: Total Blood Loss

Summary: the aim of our study is to determine whether the use of a tourniquet during tka would affect total measured blood loss , operation time, postoperative complications; hemoglobin concentration; limb swelling and postoperative pain.

tourniquets are widely used in total knee arthroplasty (tka) . tka has been reported to be associated with significant blood loss which at times necessitates transfusion. although the tourniquet is widely used by orthopedic surgeons, its role is controversial . several studies have shown that using a tourniquet in tka could reduce the total blood loss, while results from others indicated the opposite . therefore the relationship between the use of a tourniquet and the total blood loss of patients undergoing tka is still unclear. the use of a tourniquet is believed to be effective for decreasing intraoperative blood loss and creating a bloodless surgical field, which theoretically would facilitate the cementing technique and other surgical procedures. however, reactive blood flow reaches its peak within five minutes after the tourniquet has been released complications reported as a consequence of tourniquet application are skin injury \[skin abrasions, blisters, breaks , pressure necrosis\], nerve injury, post tourniquet syndrome, deep venous thrombosis, postoperative pain, wound healing disorders and early infections

Eligibility criteria:
inclusion criteria: * any patient with knee osteoarthritis undergoing primary total knee arthroplasty exclusion criteria: 1. patients with hemorrhagic disease 2. patient with revision total knee arthroplasty 3. patient with history of vascular thrombosis 4. patients taking anti-platelet agents due to cardiovascular disease 5. patients with hemoglobin level below 10gm/dl

Keywords: total knee arthroplasty
comparison of effectiveness of two different electrotherapy agents on central sensitization

Conditions: Osteoarthritis, Knee

Summary: the aim of this study is to compare the efficacy of transcutaneous electrical nerve stimulation (tens), interferential currents (ifcs) and sham devices in improving central sensitization (cs) findings, including pressure pain thresholds, pain catastrophizing, depression, and kinesiophobia in patients with knee osteoarthritis (oa).

knee oa, which is the most frequently encountered type of oa is a leading cause of disability and chronic pain. cs is as important as nociceptive component in the pathogenesis of oa-related pain. therefore, the necessary interventions for cs should be also considered when deciding the treatment protocol.tens and ifc have been safely and commonly employed in the conservative treatment of knee oa. however, there are limited and inconsistent data concerning the impact of these modalities on cs component of pain.therefore, the aim of this study is to investigate whether these agents are effective on cs and they are superior to each other.

Eligibility criteria:
inclusion criteria: 40 to 75 years of age, having bilateral knee oa radiologically with a kellgren-lawrence grade of 2 or 3. reporting knee pain of more than 3 on the visual analog scale (vas) over the last 6 months being unfamiliar with tens and ifc use - exclusion criteria: 1. having the history of any contraindication for electrotherapy (pacemakers, epilepsy, dermatological conditions, abnormal sensation in the knees, pregnancy), 2. having a knee surgery or intra-articular corticosteroid or hyaluronic acid injection within 6 months. 3. taking any drugs acting on the nervous system such as anticonvulsants, antidepressants, myorelaxants, or opioid drugs in the study period. 4. having fibromyalgia, inflammatory rheumatologic, severe psychological disorders -

Keywords: physical therapy modalities osteoarthritis knee central nervous system sensitization pain electric stimulation therapy
prevention of acute kidney injury after transcatheter aortic valve implantation

Conditions: Acute Kidney Injury

Summary: randomized controlled, single-center trial randomizing patients with chronic kidney disease and symptomatic severe aortic valve stenosis undergoing transcatheter aortic valve implantation (tavi). patients are randomized in a 1:1 ratio to periprocedural intravenous hydration matched to urine output using the renalguard system and to standard hydration. the purpose of the study is to test, wether the controlled intravenous hydration with the renalguard system is superior to standard hydration to prevent acute kidney injury after tavi.

acute kidney injury (aki) after transcatheter aortic valve implantation (tavi) is associated with worse outcome. the renalguard system was developed to prevent aki by a controlled furosemide-induced diuresis with matched isotonic intravenous hydration. it is based on the theory, that a high urinary output prevents contrast media-induced nephropathy (cin). the present study is a prospective, randomized trial to investigate wether a matched intravenous hydration using the renalguard system is superior to standard pre- and postprocedural intravenous hydration in patients with severe aortic valve stenosis and chronic kidney disease undergoing tavi. primary endpoint is the occurrence of aki after tavi.

Eligibility criteria:
inclusion criteria: * symptomatic severe aortic valve stenosis undergoing transcatheter aortic valve implantation * chronic kidney disease (baseline glomerular filtration rate ≤ 60 ml/min) * written informed consent exclusion criteria: * hemodynamic instability * dialysis-dependent chronic kidney injury * emergency transcatheter aortic valve stenosis

Keywords: transcatheter aortic valve stenosis chronic kidney disease acute kidney injury
cardiamp cell therapy chronic myocardial ischemia trial

Conditions: Refractory Angina; Chronic Myocardial Ischemia

Summary: prospective, multi-center, 2:1 randomized (treatment : sham control), sham-controlled, double-blinded trial to compare treatment using the cardiamp cell therapy system to sham treatment treatment group: subjects treated with abmc using the cardiamp cell therapy system sham control group: subjects treated with a sham treatment (no introduction of the helix transendocardial delivery catheter, no administration of abmc)


Eligibility criteria:
inclusion criteria: 1. male or female 21 to 80 years of age 2. canadian cardiovascular society (ccs) class iii or iv chronic refractory angina. 3. lack of control of angina symptoms despite maximum tolerated doses of anti-angina drugs. 4. evidence of inducible myocardial ischemia on baseline stress testing 5. obstructive coronary disease unsuitable for conventional revascularization 6. experience angina episodes at a minimum of 7 angina episodes per week (during a 4-week screening period). 7. able to complete an exercise tolerance test on the treadmill 8. left ventricular ejection fraction of greater than or equal to 40% as measured by echocardiography. 9. qualification of a pre-procedure screening of bone-marrow aspiration exclusion criteria other cardiac or vascular system or other health-related criteria which may be seen in a patient's history and physical examination.

Keywords: cardiovascular stem cell therapy bone marrow mononuclear stem cells intramyocardial injection
brain network activation analysis in epilepsy

Conditions: Epilepsy; Epilepsy, Temporal Lobe

Summary: this is a prospective study investigating the utility of brain network activation (bna) analysis in patients with epilepsy.

bna technology is based on a network model to depict functional connectivity. the descriptive network model approach provides insights regarding inter-connectivity of brain networks and can describe the temporal-spatial brain activation patterns applied to various types of data-sets including eeg, meg and fmri. in this study it is proposed that synchronization in brain activity may be disrupted in patients who experience frequent seizures and may correspond to functional impairments (e.g., memory, processing speed). as such, bna analysis may provide additional data that complement current functional assessments, inform clinical assessment and management of epilepsy, and identify subgroups of patients that might be at risk for poor treatment outcomes.

Eligibility criteria:
inclusion criteria: * participants will be between ages 18-50 years old * able to speak, read and understand english sufficiently to understand the nature of the study, and to allow completion of all study assessments * willingness to participate and able to give informed consent * if corrected vision: only glasses should be used during the study testing exclusion criteria: * history of significant head trauma * evidence of other neurologic disease * any diagnosed psychiatric or systemic condition that could lead to a change in brain activity or volume (e.g., stroke, alzheimer's disease, alcoholism). * currently with lice or open wounds on scalp * significant sensory deficits * use of a hearing aid that occupies the ear canal * substance abuse in the last 3 months and any clinically significant substance dependency * additional exclusion criteria for controls are a history of any neurological disease or psychological illness.